INTRODUCTION
At the time Oscar Ratnoff was born, in 1916, only rudimentary knowledge of the blood coagulation mechanisms existed. This was summarized by Paul Morawitz (1958) and was based on the work of several eighteenth and nineteenth century scientists. As can be seen in Fig 1, it was known that fibrinogen was converted to fibrin by the enzyme thrombin, and that thrombin existed as a precursor, prothrombin. Prothrombin was thought to be converted to thrombin by 'thrombokinase', which, according to Morawitz, could be derived from blood platelets or from damaged tissue. Calcium was also known to be necessary for these reactions. Even though Morawitz's scheme was accepted in the early 1900s as explaining the factors necessary for the formation of a fibrin clot, some investigators at that time were aware that other plasma factors were also needed for the normal conversion of prothrombin to thrombin. Evidence that other factors were necessary was demonstrated in 1936, when Warner and colleagues at the University of Iowa developed a two-stage prothrombin assay, and showed that both plasma and serum factors, in addition to tissue factor, were required for the normal rate of conversion of prothrombin to thrombin (Warner et al, 1936) . Patek and Stetson (1936) reported that haemophilic patients were deficient in a factor or factors present in the globulin fraction of normal plasma, a factor they termed antihaemophilic factor (AHF) or antihaemophilic globulin (AHG).
This amount of knowledge was essentially the state of affairs in 1939 when Oscar Ratnoff graduated from Columbia University College of Physicians and Surgeons. After graduation, he became an intern at the Johns Hopkins Hospital, and later did postdoctoral work at Harvard Medical School and Montefiore Hospital in New York before joining the United States Army to take part in the Second World War from 1943 to 1946.
The state of knowledge of blood coagulation remained essentially unchanged during the war. In 1946, Dr Ratnoff returned to Johns Hopkins as a Fellow in Haematology. While at Hopkins, he worked with C. Lockhard Conley and Robert Hartmann at a time when A. McGehee Harvey was Chair of Medicine. During his early career at Johns Hopkins, it became clear that Dr Ratnoff was destined to join a handful of very distinguished investigators from various parts of the world who would, over the next several decades, be responsible for an explosion of knowledge about the blood clotting system and the related clinical conditions of thrombosis and haemorrhage. Ratnoff's career in coagulation research began at Johns Hopkins, but the bulk of his work was accomplished after he moved to Case Western Reserve University in Cleveland, where he has remained.
Before describing Dr Ratnoff's contributions to our knowledge of blood coagulation, it is necessary that the reader be aware of the older nomenclature of the clotting factors as it existed in the 1940s and 1950s, as well as the nomenclature currently in use today (Table I) . Ratnoff never readily accepted the Roman numeral nomenclature of the clotting factors until late in his career and, in describing his contributions to coagulation research, some of the older nomenclature will be employed in the interest of history. Ratnoff's opposition to the Roman numeral nomenclature was understandable given the fact that Roman numerals were frequently transposed, such that factor IX was confused with factor XI and factor VII with factor VIII. In addition, Roman numerals are even less descriptive than the older nomenclature. However, he finally accepted Roman numeral nomenclature largely because it had become the international language of coagulation.
THE DISCOVERY OF HAGEMAN FACTOR (FACTOR XII)
In 1950, Ratnoff moved to Case Western Reserve University. Soon after his arrival, he was asked to examine a 37-year-old railroad brakeman who was found to have a prolonged glass clotting time that was obtained during routine preoperative screening. The patient had no haemorrhagic symptoms, even after tonsillectomy, dental extractions and various injuries. Detailed studies on the original Hageman-factor-deficient patient are shown in Table II (Ratnoff & Colopy, 1955; Ratnoff & Margolius, 1955) . These studies revealed that the patient had remarkably prolonged whole blood and plasma clotting times in glass and silicone-coated glass tubes. The patient's prolonged clotting time was corrected by small amounts of plasma from each of the other known clotting factor deficiencies. Ratnoff concluded that his patient was deficient in a hitherto unrecognized clotting factor which he named Hageman factor, later known as factor XII. Figure 2 depicts a photograph of the young Dr Ratnoff and Mr John Hageman, the original factor-XII-deficient patient. An original sketch of the Hageman kindred is shown in Fig 3. Shortly after the description of the Hageman trait in the original patient, Ratnoff found the same defect in a second larger kindred, in which the family tree of two sisters showed that Hageman factor deficiency was inherited as an autosomal recessive disorder (Margolius & Ratnoff, 1956) . As the grandparents of the two affected sisters were first cousins, the possible role of consanguinity leading to homozygous expression of Hageman factor deficiency appeared possible. In a much later observation that is still not explained, Ratnoff, in collaboration with others, described a family with Hageman factor deficiency that appeared to be inherited as an autosomal dominant trait (Bennett et al, 1972) .
Further experiments indicated that Hageman factor acted early in the clotting process. When plasma was carefully collected in silicone-coated tubes, Hageman factor existed in a precursor form, which could be activated by glass (Ratnoff & Rosenblum, 1958) . Thus, very early on, Ratnoff conceived of blood clotting factors circulating as inactive precursors (zymogens) that became 'activated' as clotting commenced. He later demonstrated that Hageman factor could be activated not only by glass, but also by collagen, ellagic acid, kaolin, celite and certain other negatively charged substances (Ratnoff, 1978) . Native plasma was prepared in such a way as to be virtually platelet free, accounting for the long clotting time.
Interestingly, while Ratnoff was still at Johns Hopkins, he and colleagues Robert Hartmann and Lockhard Conley described a clot-accelerating property in normal plasma that, they concluded, acted early in the clotting process Ratnoff et al, 1950) . At the time, they only described the characteristics of this activity but did not completely identify it, but this same type of 'clot-promoting activity' was not detectable in Ratnoff's original Hagemanfactor-deficient patients. Thus, it seems likely that some properties of Hageman factor were described as early as 1950, several years before patients deficient in Hageman factor were observed.
Obviously, the markedly prolonged clotting times of Hageman-factor-deficient plasma suggested to many investigators that Hageman factor must play a major role in coagulation. This assumption immediately raised the enigma that even though patients deficient in this factor exhibited strikingly long clotting times, none of them exhibited a tendency for excessive haemorrhage, even after extensive surgery or trauma. Ironically, Mr Hageman died of thrombosis (a pulmonary embolus), not haemorrhage, after many years of productive life . The lack of bleeding in patients with factor XII deficiency remained a dilemma until modern times, as will be discussed later.
KNOWLEDGE OF COAGULATION FACTORS AT THE TIME OF DISCOVERY OF HAGEMAN FACTOR (FACTOR XII)
By the time Ratnoff and Colopy described the characteristics of factor XII, the following factors had been described: von Willebrand factor (VWF, von Willebrand, 1931) , factor V (Owren, 1947) , factor VII (Alexander et al, 1951) , factor VIII (Patek & Stetson, 1936) , factor IX (Aggeler et al, 1952; Biggs et al, 1952; Shulman & Smith, 1952) and factor XI (Rosenthal et al, 1953) . Later, two groups described factor X deficiency (Telfer et al, 1956; Hougie et al, 1957) . However, it was not at all clear how these multiple factors interacted to convert prothrombin to thrombin to result in the formation of a normal fibrin clot. Acquisition of this knowledge would prove to be one of the most important contributions to the modern understanding of the blood coagulation mechanism, as was later obtained independently by Macfarlane (1964) . A perusal of Dr Ratnoff's laboratory notes from 1961 to 1964, some of which were contributed by Professor Earl Davie, reveals the sequence of events leading to the development of the waterfall hypothesis of blood coagulation: a hypothesis that attempted to demonstrate the sequential reactions leading to thrombin generation and subsequent clot formation.
THE DEVELOPMENT OF THE WATERFALL THEORY OF COAGULATION
By 1958, Ratnoff was working with Earl Davie, a biochemist at Case Western Reserve University, whose career was greatly influenced by his association with Ratnoff (Fig 4) . The recruitment of Earl Davie to the field of blood coagulation is probably one of Ratnoff's greatest accomplishments, given the fact that Davie emerged as one of the leaders in the field, and cloned, sequenced and expressed most of the clotting factors.
In a publication submitted in 1960 and published in 1961, Ratnoff and Davie were able to prepare crude preparations of Hageman factor (factor XII) and factor XI . Hageman factor was prepared from plasma deficient in factor XI and was thought to be about one thousandfold more pure than the starting plasma. Factor XI was purified from plasma deficient in factor XII and was a crude preparation, thought to be about 20-fold more pure than the starting plasma. As Hageman factor preparations were prepared in glass tubes, they were activated during the preparative procedure. After activation, the Hageman factor preparation shortened the clotting time of normal plasma in silicone tubes at 37°C. When activated Hageman factor was mixed with the crude preparations of factor XI, Ratnoff and Davie noted the development of highly significant clot-accelerating activity as measured by marked shortening of a cephalin-plasma clotting time test. The effect of activated Hageman factor on factor XI was dose dependent. From these simple experiments, the authors concluded that activated Hageman factor could activate factor XI in a reaction that did not require calcium . In the same publication, the authors noted that diisopropylfluorophosphate (DFP) inhibited both factor XIIa and factor XIa, lending support to the supposition that both of these factors existed in precursor form as zymogens and that, when activated, they possessed enzymatic activity. Although Ratnoff and colleagues were the first to demonstrate that factor XI was activated by factor XIIa, this possibility had been suggested as early as 1959 (Hardisty & Margolis, 1959) .
It is clear from the paper describing the activation of factor XI by factor XIIa that Ratnoff and Davie, as well as other investigators, suspected that the substrate for factor XIa was plasma thromboplastin component (PTC, Christmas factor, factor IX). The activation of factor IX by factor XIa in the presence of calcium ions was then clearly shown by Ratnoff and Davie (1962) in experiments that led to the waterfall hypothesis. Earlier, Bergsagel and Hougie (1956) had described a product that participated in the intermediate stages of 'blood thromboplastin formation', a term that probably corresponds to a factor IXa ⁄ VIIIa complex, now often called the 'tenase' complex. Nevertheless, in 1961, no one had described a complete sequence of events that led to the classical waterfall or cascade hypothesis of blood coagulation.
In a review of Ratnoff's records, now housed in a neat but modest office at Case Western Reserve University, I found 130 labelled volumes of carefully collected notes detailing the daily activities of Dr Ratnoff and colleagues from the early 1950s to 2001. An entry from 1962 describing the state of research on the sequence of the coagulation reactions is shown in Fig 5. The notes indicated that the coagulation scheme was being developed in collaboration with Earl Davie (who had moved to Seattle) with the help of graduate students Henry Kingdon and Roger Lundblad, and with the consultant advice of Professor Cecil Hougie. A direct quote (except for the Roman numerals) from these notes is as follows:
'Hageman factor [factor XII], plasma thromboplastin antecedent [factor XI], Christmas factor [factor IX], and antihaemophilic factor [factor VIII] are protein components present in normal plasma that participate in the early stages of clotting. Hageman factor is in an inactive form in freshly drawn blood but on contact with glass or other absorbents changes to its active form. This reaction will initiate the following chain of events (Fig 5) and eventually lead to a fibrin clot in human plasma.' Note that at this time, the specific roles of Stuart factor (factor X), proaccelerin (factor V) and platelets were Xa, in turn, was thought to activate proaccelerin (factor Va). Factor Va, in the presence of phospholipids, was thought to convert prothrombin to thrombin. It is interesting to note that phospholipid was used in the place of platelets. These data were recorded on 8 January 1963. As can be seen, the reactions could be condensed to schematically represent a waterfall. As a result of these experiments, they published the concept of their coagulation sequence in September 1964 in the journal Science (Fig 8) . Note that the figure published in Science is essentially the same as that in Ratnoff's lab notes shown in 'The initial reaction in vitro is started by glass which converts Hageman factor from inactive to an active form. Our present investigations have centred on the activated Christmas factor which appears to activate antihemophilic factor which in turn probably activates Stuart factor. At the present time, very little is known about the nature of these activation processes. Our present research interests have centred on the study of these clotting factors before and after activation and the sequence of interaction of highly purified fractions to establish and document these reactions. A major portion of this work will be carried out in collaboration with Dr Cecil Hougie of the Department of Pathology and Clinical Hematology.' Courtesy of Dr Oscar Ratnoff. (1) they clearly noted that their hypothesis described reactions of clotting factors in cell-poor plasma (indicating platelet-poor plasma), and that these reactions described only those reactions taking place in the so-called intrinsic system and not the extrinsic system of coagulation; (2) they noted that the evidence for the described reactions varied in completeness from step to step, and they stated that 'we do not wish to imply a dogmatic view of coagulation'; (3) they depicted factors VIII and V as zymogens that were activated to enzymes and not to activated cofactors; (4) they suggested that the intrinsic system of coagulation probably overlapped with the extrinsic system of coagulation at the level of Stuart factor (factor X); (5) and finally that the reactions shown in the figure omitted the known action of some inhibitors, including antithrombin and heparin. The authors ended the article by cleverly stating 'doubtless this sequence will require modification as new clotting factors are discovered and further studies reveal the complexity of substances now assumed to be free of other clotting agents'. This paragraph was prophetic, given the discovery that neither factor VIII nor factor V were pro-enzymes but rather that they were larger precursor proteins that were activated by thrombin to become the cofactors for factors IXa and Xa respectively (Rapaport et al, 1963) .
At the time of publication of the waterfall hypothesis by Ratnoff and Davie, a strikingly similar publication of the clotting reactions was published in Nature (Macfarlane, 1964 ). Macfarlane's scheme is depicted in Fig 9. Macfarlane referred to his scheme of coagulation as the 'cascade' hypothesis of blood clotting. The differences between the waterfall and cascade hypotheses were, for the most part, non-existent except for the fact that Davie and Ratnoff preferred traditional terminology for the clotting factors while Macfarlane preferred the Roman numeral nomenclature proposed by the International Committee on the Nomenclature of Clotting Factors. Macfarlane also used the term cascade, which obviously made a great impression on Ratnoff, who later stated, 'in England an electronic amplifier is known as a cascade, and it was the amplification brought about by the successive enzymatic events that was the crux of Macfarlane's thinking.' Indeed, Macfarlane calculated that the overall gain in the coagulation response was about 1 · 10 6 -fold in the cascade, an estimate very close to more modern observations. Ratnoff was particularly impressed by Mcfarlane's concept of amplification and referred to it in his chapter on the history of coagulation (Ratnoff, 1996a) . Macfarlane, as well as Ratnoff and Davie, recognized that their organization of the clotting system did not take into account the so-called extrinsic system or the important role of tissue factor in the initiation of coagulation. Both groups recognized the importance of a phospholipid surface, and both postulated a role for platelets for in-vivo thrombin generation. Although the waterfall and cascade hypotheses represented a truly major advance in understanding the sequence of events leading to thrombin generation, later work led to modifications of both hypotheses (Østerud & Rapaport, 1977; Davie et al, 1991; Gailani & Broze, 1991; Roberts et al, 1998; Balasubramanian et al, 2002; Butenas & Mann, 2002) .
It is now generally accepted that the initiation of coagulation takes place by the interaction of tissue factor and factor VII, which serve to activate both factor IX and factor X. Factor IXa and factor Xa then initiate reactions that lead to thrombin generation on activated platelet surfaces (Broze, 1992; Nemerson, 1995; Roberts et al, 1998; Butenas & Mann, 2002) . Nevertheless, the waterfall and cascade hypotheses of coagulation formed the basis of our modern concept of coagulation and provided a logical explanation of the coagulation reactions in glass tubes. These hypotheses also led to a classical algorithm for the diagnosis of hereditary bleeding disorders based on the prothrombin time and partial thromboplastin time, as shown Table III. FURTHER OBSERVATIONS ON THE SO-CALLED CONTACT FACTORS Factor XII deficiency was the first description of a patient who had a markedly prolonged partial thromboplastin time but no history of excessive bleeding. Subsequently, however, two other factor deficiencies were discovered with similar characteristics. Fletcher factor deficiency was first reported by Hathaway et al (1965) and was subsequently identified as a deficiency of prekallikrein (PK). Later, in 1975, Fitzgerald factor was described by Saito et al (1975) , and was, like Fletcher factor and Hageman factor, found to be deficient in a patient with no history of excessive bleeding but with a markedly prolonged partial thromboplastin time.
In the same year that Fitzgerald factor was described, several other groups described a similar factor, such that Fitzgerald factor was also called Flaujeac factor and Williams factor (Colman et al, 1975; Wuepper et al, 1975) . Plasma from all these patients proved to be deficient in intrinsic clotting, fibrinolytic and kinin activities. Later, Fitzgerald factor was identified as high-molecular-weight kininogen (HK), which proved to be a co-factor for the activation of factor XII and factor XI (Donaldson et al, 1976) . Ratnoff and Davie both recognized that their earlier preparations of factor XI were probably contaminated with high-molecular-weight kininogen and perhaps prekallikrein as well (Schiffman et al, 1960) .
Even before the discovery of high-molecular-weight kininogen, Ratnoff suspected that factors XII, XI and prekallikrein played a role in fibrinolysis, kinin production, blood pressure regulation and vascular permeability as well as in coagulation (Ratnoff, 1971) . He believed that these factors participated in the inflammatory reaction, one of the most important host defence mechanisms of the body.
Even though much was written about the 'contact system' and the how the various contact factors interacted, the precise nature of the interactions and the function of the end products were not completely elucidated. Furthermore, the lack of a bleeding tendency in patients deficient in the 'contact factors' raised the question as to whether factor XII, prekallikrein and high-molecular-weight kininogen played a role in in-vivo coagulation at all. More recently, several investigators have clarified some of these questions. Naito and Fujikawa (1991) , and Gailani and Broze (1993) , for example, showed that thrombin was an efficient activator of factor XI, an observation confirmed on activated platelets by Oliver et al (1999) . Their studies suggested that thrombin was indeed the physiological activator of factor XI.
Schmaier (2002) and Colman (1999) , as well as others, have delineated more clearly the physiological role of factors 
Normal › High-molecular-weight kininogen § Normal › *In afibrinogenaemia, clotting times are infinite. Factor VIII and IX deficiencies are X-linked recessive disorders so deficiency occurs only in males.
àFactor XI deficiency occurs in males and females, and causes mild bleeding symptoms. §Deficiency in these factors is not associated with bleeding. › indicates raised clotting times. XII, XI, PK, HK and the complement factor C 1 q. Mahdi et al (2002) have presented evidence suggesting that prekallikrein and factor XI assemble onto endothelial cells to form a multiprotein receptor complex composed of C 1 q, urokinase, plasminogen activator receptor and cytokeratin-1 in a reaction requiring high-molecular-weight kininogen. When factor XII and PK are assembled on this complex, PK is activated to kallikrein by prolylcarboxypeptidase. Kallikrein then activates factor XII. Schmaier (2002) suggests that the plasma kallikrein-kinin system may play a role in modulating the renin-angiotensin system to lower blood pressure.
It is interesting to note that Ratnoff not only described factor XII and HK, but he and his co-workers also described C1q in a very early publication (Lepow et al, 1954) . The early observations of Ratnoff and colleagues, using rather crude preparations of so-called contact factors, provided astonishingly accurate insights into what modern experiments have shown, that is, the interaction of these factors with the fibrinolytic system, and factors influencing vasomotor tone.
The prolonged partial thromboplastin time characteristic of these patients is not so surprising as it seems that Hageman factor, prekallekrein and high-molecular-weight kininogen, when exposed to glass, do, in fact, activate factor XI and contribute to clotting. However, glass does not reflect the in-vivo situation, as pointed out in many of Ratnoff's papers, and reiterated by Nemerson (1988) and others (Hoffman & Monroe, 2001 ).
THE UNRAVELLING OF THE FACTOR VIII ⁄ VWF COMPLEX
When Dr Ratnoff began his research career in blood coagulation, previous investigators had shown that patients with classic haemophilia, inherited as an X-linked recessive characteristic, were deficient in activity found in the coagulant fraction of normal plasma and referred to as antihaemophilic factor (AHF), which we now know as factor VIII. As stated previously, von Willebrand, a Swedish physician working in the Å land Islands between Finland and Sweden, had described an autosomal dominant bleeding disorder characterized by bruising and mucosal bleeding from the nose and gastrointestinal tract as well as menorrhagia in women. These patients exhibited long bleeding times, which von Willebrand ascribed to a defect in platelets. It remained for three groups of investigators to discover that patients with so-called von Willebrand disease also had diminished levels of factor VIII (Alexander & Goldstein, 1953; Larrieu & Soulier, 1953; Nilsson et al, 1957) . This discovery immediately raised the question of the relationship between von Willebrand's disease (VWD) and classic haemophilia, and in particular how factor VIII could be diminished in disorders so genetically disparate. Although many investigators contributed to solving this mystery, for the purposes of this report, the contributions of three main groups will be considered, namely those of Zimmerman et al (1971) , Owen and Wagner (1972) , and Weiss and Hoyer (1973) . Ted Zimmerman (Fig 10) came to Ratnoff's laboratory in the late 1970s and began a series of immunological experiments to study factor VIII in both classic haemophilia and VWD. Zimmerman et al (1971) used a method that employed ethanol precipitation of platelet-poor normal human plasma to precipitate AHF. The precipitate was brought into solution and subjected to column chromatography to prepare a highly purified 'antihaemophilic factor' preparation, the investigators apparently thinking that they had purified only coagulant factor VIII. Using this highly purified antihaemophilic factor product, rabbit antibodies to this material were raised. The resulting antiserum contained antibodies to several plasma proteins but, after adsorption with haemophilic plasma deficient in factor VIII (AHF), the antiserum formed a single precipitant line against the highly purified antihaemophilic factor preparation. Using this particular AHF antibody, Zimmerman and Ratnoff were able to show that the antibody recognized relatively normal amounts of antigenic material in plasma from patients with classic haemophilia, as well as in the plasma of a patient with combined factor V and factor VIII deficiency. The antibody also recognized antigenic material in plasma from a normal patient who had developed a circulating anticoagulant against factor VIII. However, the same antibody detected reduced antigenic material in patients with VWD. At this time, the authors interpreted their finding to suggest that patients with VWD had a true deficiency of antihaemophilic factor, which, in their minds, represented factor VIII coagulant activity, while patients with classic haemophilia possessed factor VIII-like material that was non-functional. In later studies, the authors realized that their original 'highly purified AHF preparations' consisted mostly of VWF and only trace amounts of factor VIII coagulant activity, such that the antibody they raised to this preparation was directed, for the most part, against VWF. In a later study, the authors showed that their antibody actually detected normal amounts of VWF in patients with classic haemophilia but reduced levels in patients with VWD (Ratnoff et al, 1976) . With respect to his earlier interpretations, Dr Ratnoff's admirable comment was, 'I can only say I went where the observations took me'.
Their early immunological studies were important because they ultimately led to the discovery that the term 'antihaemophilic factor' actually encompassed what we know today to be two factors. The demonstration that VWF and factor VIII were separate factors loosely connected by non-covalent bonds was demonstrated by Owen and Wagner (1972) , and Weiss and Hoyer (1973) . These authors also demonstrated that VWF was a carrier for the factor VIII molecule and was responsible for the biological half-life of factor VIII (8-12 h). In the absence of VWF, the half-life of factor VIII in the circulation is less than 1 hour.
RATNOFF AND THE COLOSSAL TRAGEDY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) IN THE HAEMOPHILIC POPULATION
Although seldom recognized for his concerns about the safety of blood products, Ratnoff was acutely aware in the early 1980s of the potential danger of contamination of the blood supply with a putative AIDS agent. He surmized early on that AIDS was probably due to a transmissible agent that might well contaminate the nation's blood supply (Ratnoff et al, 1983) . I happened to sit beside Dr Ratnoff during a meeting at the Center for Disease Control (CDC) in Atlanta in January 1983. The CDC held this meeting with the primary purpose of identifying ways and means to prevent AIDS, and especially its transmission by transfusion of blood and blood products. The proposal by officials of the CDC was to question potential blood donors about their sexual activity and to screen donor plasma for hepatitis B as a surrogate test for AIDS. It was known that AIDS was more likely to develop in homosexual men, many of whom also had hepatitis B. This CDC proposal was vocally opposed by many of the participants at the Atlanta meeting, based on the projected expense of surrogate testing and also on the belief that questions about sexual activity infringed upon individual rights. Ratnoff strongly and adamantly supported surrogate testing because of his conviction that the nation's blood supply and blood products, like factor VIII, could be contaminated with a deadly transmissible agent. According to the report by the Institute of Medicine Committee to Study HIV Transmission Through Blood and Blood Products (1995) which investigated the AIDS crisis, Ratnoff stated in 1983 that, 'there was enough information about the danger of AHF [factor VIII] concentrates in 1983 to stop using it in favour of cryoprecipitates.' In fact, Ratnoff was referring to locally prepared cryoprecipitate from known donors. In another article (Lederman et al, 1985) , Ratnoff and co-workers concluded that, prior to 1980, neither his samples, control plasmas nor haemophilic plasmas contained antibodies to the AIDS virus. From 1980 to 1984, however, detection of antibodies to the retrovirus in haemophilic samples rose from 15% to 62%, and the increase was solely due to the detection of antibodies in haemophilic patients who were treated with factor VIII concentrates prepared from thousands of donors. On the other hand, none of the haemophilic patients treated with locally prepared cryoprecipitate were antibody positive. Ratnoff was not easily swayed from his opinions even when they were unpopular. His strong reservations about the use of blood products produced from plasma pooled from thousands of donors unfortunately went largely unheeded and, as a result, many haemophilic patients were infected with the AIDS virus.
PSYCHOGENIC PURPURA
In the early 1960s, Ratnoff recognized a syndrome characterized by painful purpuric lesions in young women. The purpura usually began as a burning sensation over the extremities and certain areas of the trunk. A similar syndrome had previously been described by Gardner and Diamond (1955) and was referred to as autoerythrocytic sensitization, so named because the purpuric lesions usually began after a traumatic accident or after surgery, and similar ecchymotic areas could be reproduced by subcutaneous injection of lysed suspensions of the patient's red cells. Ratnoff and Agle (1961) , in an initial study of these patients, observed that they had significant psychological characteristics, including hysterical and masochistic features. The profile of the patients was so striking that Agle et al (1969) originally went so far as to suggest a correlation between the psychological features of the patients and the emergence of the painful purpuric lesions through a conversion reaction. The possibility that the purpuric lesions could be produced by the nervous system response to the emotional problems, resulting in the release of kinin activity sufficient to cause purpura, was considered (Ratnoff & Agle, 1968; Ratnoff, 1996b) . Later this syndrome was referred to as 'psychogenic purpura' (Ratnoff, 1989) . By 1989, Ratnoff had collected data on over 71 similar patients (Ratnoff, 1989) . Most of his patients were women whose inflammatory purpuric lesions usually occurred days or weeks after surgery, and were virtually always associated with severe emotional stress. Ratnoff described many of his patients as having a hysterical character disorder and noted that response to the subcutaneous injections of the autologous red cells was frequently negative. Clearly, he considered 'psychogenic purpura' to be a dilemma, not clearly explained by organic causes nor as a direct result of a psychiatric disorder (Ratnoff, 1989) . Nevertheless, nearly all patients exhibited significant and often similar psychological profiles. To this day, the true aetiology and pathogenesis of 'psychogenic purpura' remain an enigma, and the relationship of the purpuric lesions to the psychological profile of patients remains unclear.
RATNOFF: PHYSICIAN, SCIENTIST AND ACADEMICIAN Oscar Ratnoff's career spans the golden age of discovery in the coagulation field. Though all of his important observations cannot be detailed in this report, his career began by adding to the descriptive physiological observations of the late nineteenth and early twentieth century investigators. His early biological assays and crude preparations were succeeded by progressively purer preparations of the clotting factors and better assays. His career has led to major advances in our knowledge of coagulation, and the 'waterfall hypothesis' led to our modern concept of clotting. He has kept up with modern technological advances, as Fig 12. Colleagues of Dr Ratnoff. This photo was taken in 1958 in Rome, at a meeting to ascribe Roman numerals to the clotting factors. Names from left to right, front (kneeling): B. Alexander, USA; R. Hunter, UK; I. Wright, USA; K. Brinkhous, USA; T. Astrup, Denmark; P. de Nicola, Italy; and A. Quick, USA (standing). Back (standing): H. Jensen, USA; W. Seegers, USA; E. Jorpes, Sweden; F. Koller, Switzerland; I. Deutsch, Austria; J.-P. Soulier, France; K. Lenggenhager, Switzerland; P. Owren, Norway; L.B. Jaques, Canada; and M. Verstraete, Belgium. Dr Alexander and colleagues described factor VII deficiency. Dr Brinkhous developed the partial thromboplastin time. Dr Astrup is known for his work on fibrinolysis. Dr Quick described the prothrombin time. Dr Seegers purified prothrombin and many of the vitamin-K-dependent clotting factors, many of which he considered to be derived from prothrombin. Drs Jacques and Jorpes were known for their work on heparin. Dr Soulier made one of the first factor IX products. Dr Owren described factor V deficiency. Dr Verstraete is known for his work on clinical trials and for the establishment of the Vascular Biology Centre in Leuven. Drs Ratnoff and Macfarlane were absent from this meeting but their influence was felt nonetheless. Photo reproduced from the Archives of the ISTH, with permission. evidenced by his later papers. In recent publications, for example, he described the genetic variants of factor XI (Asakai et al, 1989) . In the 1990s, he published papers on gene therapy of haemophilia B using retroviral vectors (Perkol et al, 1993; Perales et al, 1994) . Throughout his career, he worked not only in the laboratory, but he also continued to see patients and maintained his excellent clinical credentials. In addition, throughout his career, he continued to train numerous medical students, residents and fellows, all of whom recognized Dr Ratnoff as a superb, unforgettable and knowledgeable teacher (Fig 11) .
Through all of his endeavours, Oscar Ratnoff has maintained a questioning and often iconoclastic attitude, leading to a high standard of research and patient care. He is one of the few remaining scientists from an outstanding group of coagulation experts whose collective discoveries have led to remarkable advances in our knowledge of blood coagulation and the associated haemorrhagic and thrombotic disorders. Some of his coagulation colleagues are shown in Fig 12. Oscar Ratnoff is, without question, one of the outstanding investigators in the field of coagulation. He is well known for his strong opinions, but they have always been based on data. His debates, though sometimes 'rough and tough', were always friendly and constructive and frequently entertaining. Although Dr Ratnoff still maintains his office at Case Western Reserve University, he is no longer engaged in active investigation. During my visit with him in the winter of 2002, his expression reflected his inherent inquisitiveness, and his eyes still twinkled with excitement as if he were about to challenge his colleagues, yet again, about some aspect of coagulation research. Those of us old enough to remember Ratnoff and colleagues debating the issues of the day can only reminisce about how much fun it was to hear and to listen to these great men describe their discoveries during a golden era of coagulation research. 
